Web3, the up-and-coming decentralized iteration of the World Wide Web built on the blockchain, presents a unique opportunity for fashion
Continue Reading Fashion Meets Web3 – Protecting Emerging Phygital Fashion Innovations

Web3, the up-and-coming decentralized iteration of the World Wide Web built on the blockchain, presents a unique opportunity for fashion…
Continue Reading Fashion Meets Web3 – Protecting Emerging Phygital Fashion Innovations
Several patent litigations have been filed involving mRNA pioneers such as Moderna, Inc. and BioNTech, Inc. (with Pfizer) over the…
Continue Reading The Current mRNA/LNP Patent Litigation Landscape
On August 16, 2022, Merck (NYSE: MRK) and Orna Therapeutics each announced that they entered into a collaboration agreement relating…
Continue Reading Merck and Orna Therapeutics Join Forces in Circular RNA Collaboration
In light of Elon Musk’s recent offer to buy Twitter, Inc. (“Twitter”) there has been a resurgence in the desire…
Continue Reading Increased Innovation in Decentralized Social Networks Space Spurred By Ownership Uncertainty of Traditional Platforms
Background
The food tech industry has been rapidly growing in recent years with the rise in popularity of alternative (“alt-“)…
Continue Reading Foodtech Pioneer Impossible Foods Sues Competitor Motif for Patent Infringement
In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market.
Continue Reading mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook
Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to…
Continue Reading Alphabet Dives Further Into AI-Driven Drug Discovery
Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in …
Continue Reading Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems
On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options…
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million
On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop…
Continue Reading Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy
We use cookies to enhance your user experience. By continuing to use this site you are giving your consent for us to use cookies. For more information, please see our Privacy Policy.